Lilly to pay Connecticut $25.1 million in Zyprexa probe
This article was originally published in Scrip
Executive Summary
Lilly has settled another lawsuit with a US state alleging the company marketed its antipsychotic Zyprexa (olanzapine) for off-label uses. The company is set to pay Connecticut $25.1 million to resolve all claims in a 2008 lawsuit brought by Attorney General Richard Blumenthal, which also alleged that Lilly concealed the drug's side-effects for more than a decade.